Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Pfizer Inc. : Pfizer CEO 2011 Compensation Valued At $25 Million, Up 44% Vs 2010

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/15/2012 | 10:07pm CEST
  By Peter Loftus 
  Of  
 

Pfizer Inc. (>> Pfizer Inc.) Chief Executive Ian Read received compensation valued at $25 million for 2011, up 44% from 2010, largely reflecting his promotion to the drug maker's top executive post in December 2010.

Read's compensation also was based partly on Pfizer exceeding targets set by the board's compensation committee for 2011 revenue, adjusted earnings and cash flow from operations, according to a proxy statement filed Thursday with the U.S. Securities and Exchange Commission.

The compensation committee cited Read's role in pursuing divestitures of noncore businesses and in returning cash to shareholders through dividends and share repurchases. Pfizer shares rose 23.6% for 2011.

Read, 58 years old, took over as Pfizer CEO in December 2010 when Jeffrey Kindler unexpectedly left the company. Read added the title of chairman of the board in December 2011.

For 2011, several elements of Read's compensation increased considerably. Stock awards rose to $5.7 million from $2.7 million, while the value of option awards surged to $6.9 million from less than $1 million, according to the proxy.

Read's salary was $1.7 million and his non-equity incentive plan compensation was $3.5 million. Other elements of his compensation: $6.9 million change in pension value and non-qualified deferred compensation earnings, and $319,000 in all other compensation.

For 2012, Read's salary will increase to $1.75 million, Pfizer said in the proxy.

Read, who joined Pfizer in 1978, has accumulated pension benefits with a total present value of about $27.4 million. In addition, the aggregate balance of Read's non-qualified deferred compensation is $8.2 million.

Pfizer Chief Financial Officer Frank D'Amelio received total compensation valued at $7.7 million for 2011, versus $6.5 million in 2010. Mikael Dolsten, president of worldwide research and development, received 2011 compensation valued at $7 million, up from $5.9 million for 2010.

Pfizer also disclosed in its proxy that its board compensation committee has made certain changes in executive pay in response to a disappointing shareholder advisory vote on executive compensation at last year's annual meeting.

The company has modified the terms of performance share awards so that they'll align more closely with performance, and has provided more a detailed explanation of its performance metrics, according to the proxy.

The compensation committee attributed the disappointing advisory vote at last year's annual shareholder meeting to dissatisfaction with the separation agreement with Kindler in late 2010. That agreement included a cash severance payment of $4.5 million and other compensation.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; [email protected]

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
06/28 PFIZER : Global Tyrosine Kinase Inhibitor Market 2017 - Merck, Novartis, Pfizer,..
06/28 PFIZER : breaks ground on new $236 million Chesterfield research campus
06/27 PFIZER : Breaks Ground on New R&D Facility in Chesterfield, Missouri
06/24 PFIZER : FDA To Discuss Mylotarg Again And Nabriva`s Pivotal Antibiotic Data
06/24 PFIZER : scientists devise 2-pronged attack against blood cancers
06/24 PFIZER : FDA rejects Pfizer`s Epogen biosimilar for the second time
06/24 PFIZER : US FDA rejects Pfizer`s Epogen biosimilar citing McPherson site warning
06/23 ROCHE : Why competition is key to cutting the cost of cancer drugs in South Afri..
06/23 PFIZER : Global Latanoprost Sales Market 2017 - Pfizer, Jamp Pharma, Laboratoire..
06/23 ROCHE : Why Competition Is Key to Cutting the Cost of Cancer Drugs in South Afri..
More news
Sector news : Pharmaceuticals - NEC
02:19a MYLAN : More than a third of Mylan investors voted against chairman
06/28 UK blue chips led lower by Hargreaves as strong pound takes toll
06/28DJVECTURA : In Asthma Collaboration With Novartis's Sandoz
06/28DJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
06/28DJMERCK AND : Today's Top Supply Chain and Logistics News From WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Advertisement
Financials ($)
Sales 2017 52 736 M
EBIT 2017 19 871 M
Net income 2017 10 814 M
Debt 2017 25 179 M
Yield 2017 3,80%
P/E ratio 2017 17,05
P/E ratio 2018 15,26
EV / Sales 2017 4,29x
EV / Sales 2018 3,99x
Capitalization 201 105 M
More Financials
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 37,4 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Ole Isacson Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC201 105
JOHNSON & JOHNSON18.34%363 694
ROCHE HOLDING LTD.8.21%224 549
NOVARTIS12.55%222 848
PFIZER3.97%201 105
MERCK AND COMPANY11.33%179 263
More Results